Publications by authors named "Ingrid Mandjes"

Claim this Profile
N
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Iris Nederlof, Olga I Isaeva, Manon de Graaf, Robbert C A M Gielen, Noor A M Bakker, Ingrid A M Mandjes

Nat Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Mark Opdam, Annelot G J van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M Horlings, Ingrid A M Mandjes

iScience· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
Sonja Vliek, Florentine S Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels

NPJ Breast Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Leonie Voorwerk, Olga I Isaeva, Hugo M Horlings, Sara Balduzzi, Maksim Chelushkin, Ingrid A M Mandjes

Nat Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Lennart Kester, Danielle Seinstra, Annelot G J van Rossum, Claire Vennin, Marlous Hoogstraat, Ingrid A M Mandjes

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).
Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, Harm van Tinteren, A Elise van Leeuwen-Stok

Breast Care (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.
Stacey E P Joosten, Marius Wellenstein, Rutger Koornstra, Annelot van Rossum, Joyce Sanders, Ingrid A M Mandjes

NPJ Breast Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
Anna van der Voort, Mette S van Ramshorst, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper

JAMA Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Richard D Baird, Annelot G J van Rossum, Mafalda Oliveira, Karin Beelen, Meiling Gao, Ingrid A M Mandjes

Clin Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Ingrid A M Mandjes

Nat Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Ingrid A M Mandjes

Nat Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
Annelot G J van Rossum, Marleen Kok, Danielle McCool, Mark Opdam, Nienke C Miltenburg, Ingrid A M Mandjes

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
Mette S van Ramshorst, Erik van Werkhoven, Ingrid A M Mandjes, Margaret Schot, Jelle Wesseling

Eur J Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Mette S van Ramshorst, Erik van Werkhoven, Aafke H Honkoop, Vincent O Dezentjé, Irma M Oving, Ingrid A Mandjes

Breast· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
Hedde D Biesma, Philip C Schouten, Miangela M Lacle, Joyce Sanders, Wim Brugman, Ingrid Mandjes

Genes Chromosomes Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.
Gabe S Sonke, Ingrid A Mandjes, Marjo J Holtkamp, Margaret Schot, Erik van Werkhoven

Breast J· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis